Shanghai, China; Paris, France – June 30, 2026 – CloudScientific, a leading provider of integrated scientific software solutions for the life sciences sector in China, today announced a strategic distribution partnership with DeepLife, a Paris-based AI-driven techbio company, to bring virtual cell technology to support drug discovery and translational research to the Chinese market.

DeepLife, founded in 2019, is a techbio company on a mission to cure disease one cell at a time. The company develops digital twins of cells by integrating multi-omics data, artificial intelligence, and systems biology. Its flagship platform, TwinCell, is a Large Causal Cell Model (LCCM) that identifies the key regulators driving cells from diseased to healthy states. By combining single-cell embeddings with multi-omics networks, TwinCell generates causal predictions that follow biologically plausible pathways, delivering targets that are actionable and mechanistically interpretable.

TwinCell is built on a foundation of over 1 billion harmonized single-cell multi-omics data points from public and proprietary sources. The platform enables cell-type-specific precision modeling, causal target identification, and drug repositioning analysis. DeepLife's AI-driven approach is designed to de-risk and compress timelines in target discovery and drug repositioning screening, improving development decision-making and reducing downstream uncertainty. The company has established R&D collaborations across multiple therapeutic areas including skin autoimmune diseases, as well as neurodegenerative disorders.

CloudScientific, founded in Shanghai in 2009, has spent over 16 years helping international scientific software providers reach and support research teams across China. The company serves more than 1,200 biopharmaceutical companies, academic institutions, and research organisations, with a portfolio spanning computational chemistry, drug design, cheminformatics, bioinformatics, proteomics, and clinical data analytics.

This partnership combines DeepLife's cutting-edge AI-powered virtual cell technology with CloudScientific's deep local market expertise, established distribution network, and proven technical support capabilities. Chinese biopharmaceutical companies and research institutions will now have access to DeepLife's full suite of solutions through CloudScientific, including TwinCell virtual cell modeling, disease single-cell atlas construction, and AI-driven target discovery and drug repositioning.

"We are thrilled to bring DeepLife's breakthrough digital twin of cell technology to China," said a representative from CloudScientific. "This represents the next paradigm in AI-powered drug discovery, and we are proud to equip Chinese researchers with these transformative tools."

"China is one of the most dynamic life science innovation markets in the world," said a representative from DeepLife. "CloudScientific's deep customer relationships and technical capabilities make them the ideal partner to introduce our virtual cell platform to the Chinese market. We look forward to accelerating the ability of Chinese scientists to understand and treat disease at the cellular level."

This strategic partnership marks a significant step forward in advancing AI-driven precision medicine in China and contributing to the technological upgrading and innovation breakthrough of the country's biopharmaceutical industry.

About CloudScientific 

Founded in Shanghai in 2009, CloudScientific is a Chinese company specialized in serving the life sciences community by providing integrated scientific software total solutions. The company offers a comprehensive range of internationally recognized software products and platforms spanning computational chemistry, drug design, cheminformatics, bioinformatics, proteomics, and clinical data analytics. CloudScientific currently serves over 1,200 biopharmaceutical enterprises and academic customers across China. For more information, visit www.cloudscientific.com.

About DeepLife

Founded in 2019 and headquartered in Paris, France, DeepLife is a techbio company developing AI-powered digital twins of human cell types to support therapeutic decision-making. Its platform, TwinCell, integrates over 1 billion harmonized single-cell multi-omics data points with causal AI and cell-type-specific biological networks to support target identification, drug repositioning, indication expansion, and disease characterization. DeepLife applies its technology across therapeutic areas, including autoimmune, inflammatory, dermatological, neurodegenerative, oncology, and cardiometabolic diseases. For more information, visit www.deeplife.co.

Media enquiries

For CloudScientific: marketing@cloudscientific.com

For DeepLife: hello@deeplife.co